Icon

ERLEADA (nda210951)- (60MG,240MG)

APALUTAMIDE JANSSEN BIOTECH
60MG,240MG
Yes No
2040-Jan-30 2023-Feb-14
None None
None No
ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. non-metastatic castration-resistant prostate cancer.
0 2 0
Total Other Developers 14
Drugs with Suitability No
60MG ** ** - - -
240MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.